Phase 1 Bladder Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have a solid tumour cancer with a specific change (called an FGFR3 pathway alteration) found through testing of a tumour or blood sample, where that change is considered meaningful for treatment
• Depending on which group (cohort) a person is assigned to, eligibility may require a diagnosis of bladder or urinary tract cancer (called urothelial cancer) that has spread locally or to other parts of the body, with or without a specific FGFR3 genetic change
• People in one group (Cohort C1) must have a solid tumour that is not urothelial cancer, that has spread locally or to other parts of the body, and has a qualifying FGFR3 genetic change
• Having a tumour that can be measured by scans is required for most groups; some groups also accept tumours that cannot be measured by standard criteria
• People who have a tumour tissue sample available for testing (those without enough tissue may still be considered after review by the trial team)
• People who are well enough to carry out daily activities — this is measured using a standard scale, with stricter fitness requirements for some groups than others
• People who have already received certain prior cancer treatments, with the number of prior treatments required varying depending on the group assigned (confirm with trial site)
• People in one group (Cohort B5) who have not yet received any systemic treatment for locally advanced or metastatic urothelial cancer
• Prior treatment with a type of drug called an FGFR inhibitor is allowed for some groups, required for others (Cohorts B1 and B4 require prior treatment with a drug called erdafitinib), and not permitted for others (Cohorts B2, B5, and C1)

Who may not be able to join:

• People whose cancer started in the brain or spinal cord (primary central nervous system cancer)
• People who have cancer that has spread to the brain or spinal cord and has not been treated or is not well controlled
• People with active eye conditions affecting the cornea or retina (those with mild eye conditions that are not causing symptoms may still be considered)
• People who still have serious side effects from previous cancer treatments that have not resolved
• People with significant heart or cardiovascular problems
• People with a particular irregularity in their heart's electrical activity (an abnormal heart rhythm measurement called a prolonged QTcF interval)
• People with an active, uncontrolled infection or other serious ongoing medical conditions
• People who are currently pregnant, breastfeeding, or planning to breastfeed during the study or within 6 months of the last dose of the study treatment (people who have already stopped breastfeeding may be considered)

Important: Always verify eligibility with the trial site directly before applying.